CN102988486A - New application of cinnamon oil and cinnamaldehyde serving as main component thereof in lung cancer resistance - Google Patents
New application of cinnamon oil and cinnamaldehyde serving as main component thereof in lung cancer resistance Download PDFInfo
- Publication number
- CN102988486A CN102988486A CN2012103469017A CN201210346901A CN102988486A CN 102988486 A CN102988486 A CN 102988486A CN 2012103469017 A CN2012103469017 A CN 2012103469017A CN 201210346901 A CN201210346901 A CN 201210346901A CN 102988486 A CN102988486 A CN 102988486A
- Authority
- CN
- China
- Prior art keywords
- cinnamaldehyde
- serving
- cinnamic aldehyde
- cinnamon oil
- main component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention aims to provide new application of cinnamon oil and cinnamaldehyde serving as a main component thereof in lung cancer resistance. Researches with a method of methyl thiazolyl tetrazolium (MTT) and the like prove that the cinnamon oil and the cinnamaldehyde serving as the main component thereof have a remarkable inhibiting effect on A549, and cinnamic acid serving as a metabolic end product of the cinnamaldehyde does not have or has extremely weak inhibiting effect on the A549. The cinnamon oil and the cinnamaldehyde serving as the main component thereof can be applied to preparation of a lung cancer resistant medicament, and can be pharmaceutically prepared into multiple formulations such as powder, tablets, pills, capsules, soft capsules, nano emulsion and injection. The new application has the main advantages that the cinnamon oil and the cinnamaldehyde serving as the main component thereof are very rich in raw material, low in price and low in toxic or side effect; the formulation is easy to select; the components of the preparation are definite; the preparation process and the quality standard are convenient to control; and the cinnamon oil and the cinnamaldehyde have good market compliance and application prospect.
Description
Affiliated technical field
The invention belongs to medical technical field, exactly is the new purposes of Oleum Cinnamomi and the anti-pulmonary carcinoma of main constituent cinnamic aldehyde thereof.
Background technology
Cortex Cinnamomi is the dry bark of canella Cortex Cinnamomi Cinnamomum cassia Pres1..Oleum Cinnamomi also claims Oleum Cinnamomi, for the dry skin of Cortex Cinnamomi, the volatile oil that leaf obtains through vapor distillation, is the supernatant liquid of yellow or brown color, and the special fragrance of Cortex Cinnamomi is arranged, and it is sweet to distinguish the flavor of, relative density 1.055-1.070, index of refraction 1.602-1.614.Oleum Cinnamomi confirms that through the GC-MS analysis and research chemical constituent wherein mainly contains cinnamic aldehyde, acetic acid Cortex cinnamomi japonici (Ramulus Cinnamomi) ester, salicylide and cinnamic acid etc., and the relative amount of cinnamic aldehyde is up to more than 87%; Oleum Cinnamomi has stronger volatility, and it is unstable to meet light and heat, and the pharmacological action of volatile oil is had a significant effect.Cinnamic aldehyde has another name called cinnamic aldehyde, phenylacrolein etc., chemistry 3-phenyl by name-2-acrylic aldehyde, English Cinnamic aldehyde by name; Has strong Cortex Cinnamomi fragrance and lasting.Cinnamic aldehyde is insoluble in water, glycerol and petroleum ether, is soluble in ethanol, the ether, can volatilize with steam; Unstable in highly acid or strongly basic medium, easily cause variable color, easily oxidation in air; Oxidation reaction occurs and changes into cinnamic acid (also being called cinnamic acid) in cinnamic aldehyde in vivo.
Research finds, that cinnamic acid has is antibiotic [Li Xiaofang etc. synthetic, the bacteriostatic activity of cinnamic acid-oxine rare earth compounding and to the effect of DNA. research and development of natural products, 2012; 24 (2): 160-163], anticancer [
Lv JunmingDeng. cinnamic acid associating Ndfip1 is to the cooperative effect of human liver cancer cell SMMC-7721 Cell apoptosis and proliferation. practical clinical medical magazine, 2011; 15 (2): 27-30; Zhang Kejian etc. cinnamic acid is induced the NB apoptosis. Wuhan University Journal-medicine, 2003,24 (4): 327; Red legend deep pool etc. cinnamic acid associating vitamin C is to the cell induction differentiation of HL-60. treatment and prevention of tumour research, 2003,30 (2): 92] effect, external suppress melanotic tumor and hepatoma cell proliferation and its differentiation of promotion [Huang Wei etc. cinnamic acid is induced the research of BEL-7402 human liver cancer cell differentiation. practical cancer magazine, 2000,15:12], can indirectly be incorporated into the expression of some gene of the upper regulation and control of DNA, block the growing multiplication of tumor cell and show [zhang Q H without fetal toxicity, ShengH P, LohTT.Bcl-2protects HL-60cells from apoptosis by stabilixzing their intracelular calciun pools.Life Sci, 2001,68 (2): 873]; Other have the report cinnamic acid can be used for treating tuberculosis [Li Wenlan etc. the pharmacokinetics comparative study of separate sources cinnamic acid, CHINA JOURNAL OF CHINESE MATERIA MEDICA, 2008; 33 (10): 1192-1195] etc.Cinnamic acid etc. in the fields such as medicine, food additive, cosmetics, agricultural chemicals, also be widely used [Liu Jingtao etc. cinnamic acid derivative synthetic. seek medical advice and medicine (second monthly magazine), 2012; 10 (1): 351-352].
Oleum Cinnamomi and main constituent cinnamic aldehyde thereof have multiple physiologically active and medical value.Yi Xing etc. [high effective liquid chromatography for measuring of Determination of Cinnamaldehyde in the cinnamon oil microemulsion. the time precious traditional Chinese medical science traditional Chinese medicines, 2011; 22 (6): 1325-1326] report: " Oleum Cinnamomi is widely used in medicine, food and light industry industry.Modern study shows, the multiple effects such as that Cortex Cinnamomi has is antibiotic, antitumor, antiulcer, blood sugar lowering, antithrombotic, analgesic, analgesia, spasmolytic, tonifying YANG, parasite killing, antioxidation.Cinnamic aldehyde is the main active substances of Oleum Cinnamomi, and Determination of Cinnamaldehyde in Cinnamon Oil is very high, is about 80-95%.Cinnamic aldehyde is very unstable in blood, and oral or intravenously administrable can be oxidized to rapidly the lower cinnamic acid of pharmacologically active after entering blood, and is irreversible conversion ".
Our early-stage Study confirm Oleum Cinnamomi and main constituent cinnamic aldehyde thereof have antithrombotic [
Huang JingqunDeng. cinnamic aldehyde is to antiplatelet aggregation and thrombotic characteristics.
The Chinese Clinical rehabilitation2006; 10 (31): 34-36] and antitumor [
Huang JingqunDeng. cinnamic aldehyde is on the impact of xenografts in nude mice stomach cancer cell growth of xenografted and apoptosis.
PLA's Acta Pharmaceutica Sinica, 2006; 22 (5): 343-346] effect, and find first anti-Coxsackie virus treatment viral myocarditis [Ding Yuanyuan etc. cinnamic aldehyde is to the effect of mice Coxsackievirus B-induced viral myocarditis. research and development of natural products, 2010; 22 (5): 769-776; Yuanyuan Ding, at al.Influence of Cinnamaldehyde on Viral Myocarditis in Mice.Am J Med Sci.2010; Chinese invention patent (application number is respectively 200410073298.5,2006100429192) has been declared in the pharmacological action such as 340 (2): 114-20] in 2007.We are when the anti-non-small cell lung cancer drug of examination in the recent period, find that Oleum Cinnamomi and main constituent cinnamic aldehyde thereof have the effect of the inhibition non-small cell lung cancer cell A549 of highly significant, show that Oleum Cinnamomi and main constituent cinnamic aldehyde thereof have the prospect that is developed to treatment non-small cell lung cancer drug.
Summary of the invention
The new purposes that the purpose of this invention is to provide Oleum Cinnamomi and the anti-pulmonary carcinoma of main constituent cinnamic aldehyde thereof.We adopt the method such as MTT to studies confirm that Oleum Cinnamomi and main constituent cinnamic aldehyde thereof have remarkable inhibitory action to A549, and the metabolic end product cinnamic acid of cinnamic aldehyde does not have A549 or extremely weak inhibitory action.Oleum Cinnamomi and main constituent cinnamic aldehyde thereof can be used in the preparation anti-lung-cancer medicament, and it pharmaceutically can be prepared into multiple dosage form, such as dosage forms such as powder, tablet, pill, capsule, soft capsule, nanometer, emulsion and injections.
Advantage of the present invention is: Oleum Cinnamomi and main constituent cinnamic aldehyde raw material thereof are very abundant, cheap, and toxic and side effects is little, and dosage form is easy to select, and preparation definite ingredients, preparation technology and quality standard thereof are convenient to control, have good market compliance.
The specific embodiment
The present invention will be further described below in conjunction with embodiment.
Embodiment: Oleum Cinnamomi, cinnamic aldehyde and cinnamic acid are to the experimentation of non-small cell lung cancer cell A549 effect:
Adopt 0.25% trypsinization single-layer culturing cell A549, be made into the individual cells suspension with the RPMI1640 culture fluid that contains 10% hyclone, with every hole about 10
4Individual cell is inoculated in 96 well culture plates, every pore volume 100 μ L.Culture plate is put into CO
2Incubator is at 37 ℃, 5%CO
2And under the saturated humidity condition, cultivated one day.
It is 0.05%, 0.04%, 0.03%, 0.02%, 0.01% that Oleum Cinnamomi, cinnamic aldehyde and cinnamic acid all are mixed with final concentration, positive controls is that cisplatin injections (Nanjing Pharmaceutical Factory Co., Ltd.) final concentration of clinical practice is 0.05mg/mL, and solvent is the RPMI1640 culture fluid that does not contain hyclone.
Behind the cell culture one day, according to 3 kinds of reagents that prepare, 5 concentration of every kind of reagent add respectively in the 96 porocyte culture plates, and each concentration is established 4 multiple holes, and every hole adds 100 μ L, then continues to be placed on CO
2Incubator is at 37 ℃, 5%CO
2And cultivated 11 hours under the saturated humidity condition.11 as a child every hole add MTT solution (5mg/mL) 20 μ L, 37 ℃ are continued to hatch 4h, stop cultivating, and inhale and abandon the culture supernatant hole in, every hole adds 150 μ L DMSO, shakes 10min, Shi Jia Za fully dissolves.Select the 490nm wavelength, measure each hole absorbance value (table 1-4) at enzyme-linked immunosorbent assay instrument, take concentration as transverse axis, light is inhaled
Table 1 variable concentrations Oleum Cinnamomi detects absorbance value (A/490nm) to the MTT of non-small cell lung cancer cell A549
Table 2 variable concentrations cinnamic aldehyde detects absorbance value (A/490nm) to the MTT of non-small cell lung cancer cell A549
Table 3 variable concentrations cinnamic acid detects absorbance value (A/490nm) to the MTT of non-small cell lung cancer cell A549
Table 4 cisplatin injections detects absorbance value (A/490nm) to the MTT of non-small cell lung cancer cell A549
Receipts value (A) is drawn cell growth curve figure (seeing Figure of description 1-4) for the longitudinal axis.
Can find out that from table 1-4 and corresponding cell growth curve figure (Figure of description 1-4) thereof by contrast positive controls cisplatin injections, Oleum Cinnamomi and main constituent cinnamic aldehyde thereof have obvious inhibitory action to A549, and optium concentration is 0.05%; Cinnamic acid does not then produce or produces extremely weak inhibitory action.Oleum Cinnamomi and cinnamic aldehyde in vivo unstable easily further metabolism become cinnamic acid, and it is inhibiting to the A549 generation that hence one can see that is Oleum Cinnamomi and cinnamic aldehyde, and the metabolic end product cinnamic acid does not have or only have extremely weak inhibitory action for A549.
It is 0.05% solution that Oleum Cinnamomi, cinnamic aldehyde and cinnamic acid are mixed with concentration, add respectively in the cultured cell of 96 hole wall panels according to the MTT method, collect respectively the cell conditioned medium liquid of cultivating 3h, 10000r, 10min, 4 ℃ centrifugal, after get supernatant and carry out HPLC and detect, its mobile phase is acetonitrile-03% phosphoric acid=50: 50, records different appearance times and further analyzes wherein ingredient and content thereof.
Oleum Cinnamomi and cinnamic aldehyde in vivo unstable easily further metabolism become cinnamic acid, comprehensive MTT result, Fig. 5-10 (seeing Figure of description) was presented at reaction after 3 hours, the equal onset of Oleum Cinnamomi and cinnamic acid and the cinnamic acid peak occurred, but cinnamic acid and standard substance collection of illustrative plates no significant difference, it is Oleum Cinnamomi and cinnamic aldehyde that prompting produces inhibiting to A549, and its metabolic end product cinnamic acid does not have or only have extremely weak inhibitory action for A549.
To sum up experimental study shows, Oleum Cinnamomi and main constituent cinnamic aldehyde thereof have remarkable inhibitory action to non-small cell lung cancer cell A549, has the prospect that is developed to the treatment lung-cancer medicament.
Description of drawings
Fig. 1 is that the variable concentrations Oleum Cinnamomi is to the growth curve chart of non-small cell lung cancer cell A549;
Fig. 2 is that the variable concentrations cinnamic aldehyde is to the growth curve chart of non-small cell lung cancer cell A549;
Fig. 3 is that the variable concentrations cinnamic acid is to the growth curve chart of non-small cell lung cancer cell A549;
Fig. 4 is that 0.05mg/mL cisplatin injections positive controls is to the growth curve chart of non-small cell lung cancer cell A549;
Fig. 5 is cinnamic acid and cinnamic aldehyde;
Fig. 6 is blank group sample chromatogram figure;
Fig. 7 is Cortex Cinnamomi acidity scale product;
Fig. 8 is cinnamic acid reaction 3h;
Fig. 9 is cinnamic aldehyde reaction 3h;
Figure 10 is Oleum Cinnamomi reaction 3h.
Claims (3)
1. the new purposes of Oleum Cinnamomi and the anti-pulmonary carcinoma of main constituent cinnamic aldehyde thereof, it is characterized in that Oleum Cinnamomi and main constituent cinnamic aldehyde thereof studies confirm that through the MTT method A549 is had remarkable inhibitory action, and the metabolic end product cinnamic acid of cinnamic aldehyde does not have to A549 or extremely weak inhibitory action.
2. Oleum Cinnamomi according to claim 1 and main constituent cinnamic aldehyde thereof have effect of anti-lung cancer, it is characterized in that using in Oleum Cinnamomi and main constituent cinnamic aldehyde thereof and pharmaceutically acceptable salt thereof, ester or the medicine of sugar for the preparation for the treatment of pulmonary carcinoma.
3. Oleum Cinnamomi according to claim 1 and main constituent cinnamic aldehyde thereof the new purposes in anti-lung-cancer medicament is characterized in that Oleum Cinnamomi and main constituent cinnamic aldehyde thereof and pharmaceutically acceptable salt, ester or sugar and excipient etc. can be prepared into the pharmaceutically acceptable dosage forms such as powder, tablet, pill, capsule, soft capsule, nanometer, emulsion and injection.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103469017A CN102988486A (en) | 2012-09-18 | 2012-09-18 | New application of cinnamon oil and cinnamaldehyde serving as main component thereof in lung cancer resistance |
| PCT/CN2013/071888 WO2014044028A1 (en) | 2012-09-18 | 2013-02-26 | Anti lung cancer drug made of oleum cassiae and major constituent cinnamaldehyde thereof and use thereof |
| KR1020157000970A KR20150030725A (en) | 2012-09-18 | 2013-02-26 | Anti lung cancer drug made of oleum cassiae and major constituent cinnamaldehyde thereof and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103469017A CN102988486A (en) | 2012-09-18 | 2012-09-18 | New application of cinnamon oil and cinnamaldehyde serving as main component thereof in lung cancer resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102988486A true CN102988486A (en) | 2013-03-27 |
Family
ID=47917912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103469017A Pending CN102988486A (en) | 2012-09-18 | 2012-09-18 | New application of cinnamon oil and cinnamaldehyde serving as main component thereof in lung cancer resistance |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR20150030725A (en) |
| CN (1) | CN102988486A (en) |
| WO (1) | WO2014044028A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105963352A (en) * | 2016-06-15 | 2016-09-28 | 江苏康缘药业股份有限公司 | Cinnamon oil and application of main ingredient cinnamaldehyde of cinnamon oil |
| CN113116914A (en) * | 2021-04-19 | 2021-07-16 | 南开大学 | Pharmaceutical composition with synergistic inhibition effect on proliferation of non-small cell lung cancer A549 cells and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101460066A (en) * | 2006-03-23 | 2009-06-17 | 草药科学新加坡私人有限公司 | Extracts and methods comprising cinnamon species |
| CN101580507A (en) * | 2009-06-23 | 2009-11-18 | 华东理工大学 | Novel antitumor compound and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1086577C (en) * | 1998-10-30 | 2002-06-26 | 中国医学科学院医药生物技术研究所 | Anti-tumor noval use of cinnamamide |
-
2012
- 2012-09-18 CN CN2012103469017A patent/CN102988486A/en active Pending
-
2013
- 2013-02-26 WO PCT/CN2013/071888 patent/WO2014044028A1/en active Application Filing
- 2013-02-26 KR KR1020157000970A patent/KR20150030725A/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101460066A (en) * | 2006-03-23 | 2009-06-17 | 草药科学新加坡私人有限公司 | Extracts and methods comprising cinnamon species |
| CN101580507A (en) * | 2009-06-23 | 2009-11-18 | 华东理工大学 | Novel antitumor compound and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈立平等: "肉桂油成分分析及肉桂醛体外抗肿瘤活性研究", 《中国微生态学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105963352A (en) * | 2016-06-15 | 2016-09-28 | 江苏康缘药业股份有限公司 | Cinnamon oil and application of main ingredient cinnamaldehyde of cinnamon oil |
| CN113116914A (en) * | 2021-04-19 | 2021-07-16 | 南开大学 | Pharmaceutical composition with synergistic inhibition effect on proliferation of non-small cell lung cancer A549 cells and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150030725A (en) | 2015-03-20 |
| WO2014044028A1 (en) | 2014-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101007050B (en) | Extract of an traditional Chinese medicine containing isopsoralen, preparation method and use thereof | |
| EP1421933A1 (en) | Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus | |
| CN103316096A (en) | General flavone extract of seeds of nigella damascena l., nigella sativa l. or nigella glandulifera freyn et sint., and preparation method and use thereof | |
| CN106798762A (en) | One Plant Extracts and its preparation method and application | |
| CN104013636B (en) | Watt careless Pentacyclic triterpene saponins compounds anti-tumor drug purposes | |
| CN106138298A (en) | A kind of composition with reducing blood lipid hypoglycemic activity and preparation method and application | |
| CN105640968A (en) | Ginseng saponin combination and application thereof | |
| CN102988486A (en) | New application of cinnamon oil and cinnamaldehyde serving as main component thereof in lung cancer resistance | |
| CN101278958A (en) | Feining dropping pill and method of preparing the same | |
| CN104523742A (en) | Polysaccharide composition with effects of protecting livers and improving immunity and application of polysaccharide composition | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN102106890B (en) | Applications and preparation method of saussurea total sesquiterpene lactone | |
| CN103494860A (en) | Method for preparing lithospermum extract and application of lithospermum extract | |
| CN106822331A (en) | To lock application of the lichee bark extract based on shape polymer polyphenol in treatment antihyperuricemic disease drug or health products are prepared | |
| CN108635391A (en) | A kind of hempleaf groundsel herb phenolic acid components and the preparation method and application thereof | |
| CN101313938A (en) | Magnolia flower volatile oil spray for nose | |
| CN101259116B (en) | Externally-applied drug delivery preparations containing bullatacin part medicine exquisite articles | |
| CN101491575B (en) | Traditional Chinese medicine extract for treating atopic dermatitis and granules thereof | |
| CN103099955A (en) | Medicine pair preparation made from rhizoma polygonati and Chinese-date and having effect of cooperatively increasing non-specific immunity activity | |
| CN102961440A (en) | Pharmaceutical composition containing cyclooxygenase and natural doxorubicin or doxorubicin-like substances, its preparation method and application in preparation of multiple drugs | |
| CN101485753B (en) | Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN102100807B (en) | Chinese medicine composition for regulating qi, widening chest and relieving pain as well as detection method thereof | |
| CN104546952A (en) | Active component of selaginella doederleinii hieron as well as preparation method and use thereof | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN109464488A (en) | Honeysuckle general flavone and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130327 |
|
| WD01 | Invention patent application deemed withdrawn after publication |